Elixir’s Specialty Pharmacy Selected as One of Only 16 Pharmacies for the Limited Distribution Network of Atopic Dermatitis Medication Adbry™

January 27, 2022 – Elixir, a pharmacy benefit manager owned by Rite Aid Corporation, announced that its specialty pharmacy, Elixir Specialty, was selected by LEO Pharma as one of only 16 pharmacies across the U.S. to be part of its limited distribution network for the recently approved biologic atopic dermatitis medication, Adbry™ (tralokinumab-ldrm). Because of the complexity of biologics and other specialty medications, they are often released as limited distribution drugs (LDD) to a select network of pharmacies that can demonstrate their ability to provide the highest clinical standards, including understanding of the disease state, the ability to properly handle and store the medication, as well as provide patient monitoring, education, support and care, which is needed to optimize the treatment.

Atopic dermatitis (AD) is a chronic skin condition that affects an estimated 16.5 million adults.[1]It causes irritated skin patches that are swollen and itchy and can vary in severity, sometimes becoming unbearable and impacting quality of life. AD is associated with an immune system response where interleukin (IL) cytokines, which are secreted by immune cells, become inflamed. Adbry, indicated for the treatment of adults with moderate-to-severe AD, is the first and only FDA-approved biologic that specifically binds to the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.[2]

“Until recently, there have been very few effective treatments for atopic dermatitis,” said Jordan Maddocks, director of clinical services and outcomes for Elixir Specialty. “Adbry has the potential to provide much needed relief to our members suffering from the condition and our comprehensive care model will ensure members get the most from their treatment.”

With Elixir Specialty’s comprehensive care model, specially trained pharmacists work with AD patients before they even take their first dose of Adbry, ensuring they know what to expect, have the support they need and start therapy at an optimal time. Additionally, to ensure cost is not a barrier, Elixir Specialty will link members to available financial assistance programs. Pharmacists will continue to monitor and track the member’s progress throughout treatment, intervening when needed to provide optimal results.

[1] National Eczema Association. Eczema Stats. https://nationaleczema.org/research/eczema-facts/

[2] LEO Pharma. LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. https://www.businesswire.com/news/home/20211227005159/en/LEO-Pharma-announces-FDA-approval-of-Adbry%E2%84%A2-tralokinumab-ldrm-as-the-first-and-only-treatment-specifically-targeting-IL-13-for-adults-with-moderate-to-severe-atopic-dermatitis.